521074-77-1

Usage

Uses

Used in Pharmaceutical Industry:
6-(4-Ethylphenyl)-nicotinic acid is used as a key building block for the synthesis of various pharmaceuticals and organic compounds, leveraging its potential biological and pharmacological activities.
Used in Anti-inflammatory Applications:
6-(4-Ethylphenyl)-nicotinic acid is used as an anti-inflammatory agent, potentially mitigating inflammation and related symptoms in various conditions.
Used in Antioxidant Applications:
6-(4-Ethylphenyl)-nicotinic acid is used as an antioxidant, helping to neutralize free radicals and protect cells from oxidative damage, thereby contributing to overall health and disease prevention.
Used in Anti-cancer Applications:
6-(4-Ethylphenyl)-nicotinic acid is used as an anti-cancer agent, potentially inhibiting the growth and proliferation of cancer cells and contributing to cancer treatment strategies.
Used in Therapeutic Applications for Various Diseases and Conditions:
6-(4-Ethylphenyl)-nicotinic acid is used as a therapeutic agent for the treatment of various diseases and conditions, owing to its potential to modulate biological processes and exhibit pharmacological effects.

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 5720-05-8 4-methylphenylboronic acid 

Relevant academic research and scientific papers

Solid-phase Suzuki cross-coupling reactions using a phosphine ligand based on a phospha-adamantane framework

The use of a catalyst system based on Pd2dba3· CHCl3 and 1,3,5,7-tetramethyl-2,4,8-trioxa-6-phenyl-6-phospha- adamantane allows for Suzuki coupling aryl halides with an array of boronic acids on a solid-phase platform. The reactions can be carried out at room temperature with low palladium loadings in high yields.

Melanin-concentrating hormone antagonist

A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.